Table 1.
Metastatic step-specific anti-cancer therapeutics
| Target | Drug | Company | Metastatic steps targeted | Reference |
|---|---|---|---|---|
| MMP | Marimastat (BB-2516) | British Biotech | Extravasation | Trial NCT00003010 (Metastatic breast cancer) |
| Thrombin | Tinzaparin | Ottawa Hospital Research Institute | Survival in the circulation | Trial NCT01455831 (Metastatic colon cancer) |
| Extravasation | ||||
| Src | AZD0530 | AstraZeneca | Secondary tumor formation | Trial NCT01144481 (Risk factors for skeletal related events in breast cancer) |
| Extravasation | ||||
| EGFR | Herceptin (trastuzumab) | GlaxoSmithKline | Secondary tumor formation | Trial NCT01064349 (Breast cancer metastasis to the brain) |
| VEGFR | Dovitinib | Novartis | Extravasation | Trial NCT01262027 (Metastatic inflammatory breast cancer) |
| Secondary tumor formation | ||||
| α5β1 | Volociximab | Abbott | Extravasation | Trial NCT00100685 (Metastatic renal cell carcinoma) |
| Secondary tumor formation |